Vaxart (VXRT) reported $237M in revenue for fiscal 2025, +726.7% year on year. That ranks #2602 by revenue among 2853 SEC filers and #269 in Healthcare. Net income was $16,327, a net margin of 0.0%. Revenue has grown 21.9% a year on average since 2011 ($14.8M then). The fiscal 2025 balance sheet shows $186M in total assets, $53.8M in cash and $17.7M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenues | $237M | +726.7% | FY20252025-12-31 |
| Gross profit | Not reported | — | |
| Operating incomeOperatingIncomeLoss | $18.1M | +$84.4M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | $16,327 | +$83,275 | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $7.7M | +$52.5M | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $145,000 | −73.8% | FY20252025-12-31 |
| Total assetsAssets | $186M | +11.8% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $87.8M | +49.0% | FY20252025-12-31 |
| CashCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents | $53.8M | +113.3% | FY20252025-12-31 |
| Long-term debtLongTermDebt | $17.7M | +11.6% | FY20182018-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $39.2M | $5.2M | Open → |
| Q2 20262026-06-30 | $27.2M | −$13.5M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Vaxart, Inc.
- Ticker
- VXRT
- Exchange
- OTC
- SIC classification
- Biological Products, (No Diagnostic Substances) (2836)
- Fiscal year end
- 12-31
- CIK
- 0000072444
Filings
- 10-QAug 6, 2026Open filing →
- 10-QMay 7, 2026Open filing →
- 10-KMar 13, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Arcus BiosciencesRCUS | $247M | −$353M |
| Keros TherapeuticsKROS | $244M | $87.0M |
| Staar SurgicalSTAA | $239M | −$80.4M |
| VaxartVXRT | $237M | $16,327 |
| OrthopediatricsKIDS | $236M | −$39.6M |
| Akebia TherapeuticsAKBA | $236M | −$5.3M |
| AnaptysbioANAB | $235M | −$13.2M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Vaxart — Key figures |url=https://companiesranked.com/en/company/vaxart |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Vaxart — Key figures. CompaniesRanked. https://companiesranked.com/en/company/vaxartBibTeX
@misc{companiesranked-en-company-vaxart-2026,
author = {{CompaniesRanked}},
title = {{Vaxart — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/vaxart}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.